Search Results

You are looking at 141 - 150 of 375 items for :

  • "therapeutics" x
  • Refine by Access: All x
Clear All
Full access

NCCN Molecular Testing White Paper: Effectiveness, Efficiency, and Reimbursement

Paul F. Engstrom, Mara G. Bloom, George Daniel Demetri, Phillip G. Febbo, William Goeckeler, Marc Ladanyi, Bryan Loy, Kate Murphy, Michael Nerenberg, Paul Papagni, Mark Robson, Robert W. Sweetman, Sean Tunis, Jessica DeMartino, and Jonathan K. Larsen

-developed tests (LDTs) and released draft guidance regarding the development of companion diagnostics concurrently with therapeutics, both areas over which the FDA has regulatory authority. As recognized by the FDA, these types of diagnostic tests are used

Full access

Updates in the Management of Newly Diagnosed Acute Myeloid Leukemia

Presented by: Alice S. Mims

data, secondary AML, therapy-related disease, or CD33 positivity. “These treatment approaches have really opened up the possibility for different therapeutics for patients, but it has also made things quite a bit more complicated,” Dr. Mims noted. “So

Full access


prior to initiation of therapy. “One of the most important points we want providers to be aware of surrounds the potential for drug interactions and overlapping toxicities between cancer therapeutics and ART,” said Erin Reid, MD, UC San Diego

Full access

NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024

Featured Updates to the NCCN Guidelines

Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Mark K. Buyyounouski, Kevin Chan, Sam S. Chang, Paul Chang, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Harry W. Herr, Jean Hoffman-Censits, Hristos Kaimakliotis, Amar U. Kishan, Shilajit Kundu, Subodh M. Lele, Ronac Mamtani, Omar Y. Mian, Jeff Michalski, Jeffrey S. Montgomery, Mamta Parikh, Anthony Patterson, Charles Peyton, Elizabeth R. Plimack, Mark A. Preston, Kyle Richards, Wade J. Sexton, Arlene O. Siefker-Radtke, Tyler Stewart, Debasish Sundi, Matthew Tollefson, Jonathan Tward, Jonathan L. Wright, Carly J. Cassara, and Lisa A. Gurski

., ImmunityBio, Nonagen Biosciences, Pacific Edge, Prokarium, TU Therapeutics Inc., and UroGen Pharma; serving as a consultant for Astellas Pharma US, Inc., CG Oncology Inc., and UroGen Pharma; owning equity interest/stock options for FOLDE, TU Therapeutics Inc

Full access

Management of Advanced Stage Hodgkin Lymphoma

Ranjana Advani, Weiyun Z. Ai, and Sandra J. Horning

. Connors JM : State-of-the-art therapeutics: Hodgkin's lymphoma . J Clin Oncol 2005 ; 23 : 6400 – 6408 . 24. Diehl V Brillant C Franklin J . BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9- and HD

Full access

Shades of Survivorship

Elyse R. Park, Jeffrey Peppercorn, and Areej El-Jawahri

in its characterization of cancer survivorship. 6 However, there is need for further refinement and dissemination of this framework, particularly with advances in cancer therapeutics that can blur the lines between phases of care. Indeed, with the

Full access

Local Treatment of Malignant Brain Tumors Using Implantable Chemotherapeutic Polymers

Gary L. Gallia, Steven Brem, and Henry Brem

chemotherapy for local control of CNS metastases (Abstr #TA-06) . Neuro-Oncology 2004 ; 6 : 370 – 371 . 27 Gerson SL . MGMT: Its role in cancer aetiology and cancer therapeutics . Nature Rev Cancer 2004 ; 4 : 296 – 307 . 28 Wiestler

Full access

Where Your Data Is Going and Where It's Been

Jane M. Quigley

insurance company is a formidable additional task. When the appropriate steps are not taken to address the special circumstances surrounding the use of certain oncology therapeutics, rebilling and additional work are required. Table 2 lists an example of

Full access

DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer

Eric Lu, George V. Thomas, Yiyi Chen, Alexander W. Wyatt, Paul Lloyd, Jack Youngren, David Quigley, Raymond Bergan, Shawna Bailey, Tomasz M. Beer, Felix Y. Feng, Eric J. Small, and Joshi J. Alumkal

Michigan, and is in the process of being licensed to PFS Genomics. Dr. Small has disclosed that he has stock or other ownership interests with Fortis Therapeutics and Harpoon Therapeutics; receives honoraria from Janssen-Cilag; has a consulting and advisory

Full access

NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018

Manisha H. Shah, Whitney S. Goldner, Thorvardur R. Halfdanarson, Emily Bergsland, Jordan D. Berlin, Daniel Halperin, Jennifer Chan, Matthew H. Kulke, Al B. Benson III, Lawrence S. Blaszkowsky, Jennifer Eads, Paul F. Engstrom, Paul Fanta, Thomas Giordano, Jin He, Martin J. Heslin, Gregory P. Kalemkerian, Fouad Kandeel, Sajid A. Khan, Wajih Zaheer Kidwai, Pamela L. Kunz, Boris W. Kuvshinoff II, Christopher Lieu, Venu G. Pillarisetty, Leonard Saltz, Julie Ann Sosa, Jonathan R. Strosberg, Craig A. Sussman, Nikolaos A. Trikalinos, Nataliya A. Uboha, Jonathan Whisenant, Terence Wong, James C. Yao, Jennifer L. Burns, Ndiya Ogba, and Griselda Zuccarino-Catania

, Inc.; Symphogen Inc.; Incyte Corporation; BeiGene, Ltd.; Roche Laboratories, Inc.; Five Prime Therapeutics, Inc.; and Karyopharm Therapeutics Inc. He has also served on the advisory board for ARMO BioSciences, Inc.; Rafael Pharmaceuticals, Inc.; Five